Biogen surges ahead of key FDA decision amid mixed views on potential Alzheimer’s therapy

seekingalpha2021-06-07

Biogen(NASDAQ:BIIB) rose ~5.0%on Friday to outperform the broader market for the week as it awaits FDA approval for aducanumab, the experimental therapy against Alzheimer’s disease co-developed by the...

Source Link
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

Leave a comment
6